Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Debt: 2016-2025

Historic Non-Current Debt for Collegium Pharmaceutical (COLL) over the last 9 years, with Sep 2025 value amounting to $505.6 million.

  • Collegium Pharmaceutical's Non-Current Debt fell 10.63% to $505.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year decrease of 10.63%. This contributed to the annual value of $550.7 million for FY2024, which is 148.40% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Non-Current Debt stood at $505.6 million for Q3 2025, which was down 2.89% from $520.6 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Non-Current Debt registered a high of $565.7 million during Q3 2024, and its lowest value of $61.7 million during Q4 2021.
  • Its 3-year average for Non-Current Debt is $376.3 million, with a median of $353.8 million in 2023.
  • Per our database at Business Quant, Collegium Pharmaceutical's Non-Current Debt spiked by 544.73% in 2022 and then tumbled by 57.13% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Non-Current Debt (Quarterly) stood at $61.7 million in 2021, then soared by 544.73% to $397.6 million in 2022, then tumbled by 44.23% to $221.7 million in 2023, then surged by 148.40% to $550.7 million in 2024, then declined by 10.63% to $505.6 million in 2025.
  • Its last three reported values are $505.6 million in Q3 2025, $520.6 million for Q2 2025, and $535.7 million during Q1 2025.